Navigation Links
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
Date:5/5/2009

- Company preparing to initiate phase III clinical trial -

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that HPN-100 has received orphan product designation from the U.S. Food and Drug Administration for maintenance treatment of patients with enzymes of the urea cycle. The Company recently announced results from its phase II study and intends to initiate a phase III clinical program in this indication in the second half of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

HPN-100 is a pre-pro-drug of phenylacetic acid which is the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle deficiencies including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100 is dosed orally in liquid form.

"Receiving orphan drug designation for HPN-100 in the treatment of urea cycle disorders is an important milestone and provides meaningful benefits to the Company as we work to complete clinical trials for this investigational compound," commented Donald Santel, Chief Executive Officer of Hyperion Therapeutics.

"The designation of HPN-100 as an orphan drug for the treatment of urea cycle disorders recognizes the unmet need that remains in this patient population," said Cindy LeMons, Executive Director of the National Urea Cycle Disorders Foundation (NUCDF). "We are encouraged by this designation and look forward to initiation of the phase III clinical trials."

About Orphan Drug Designation

Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
5. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
6. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
7. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
8. Vantia Therapeutics Pipeline Continues to Mature
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
11. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009).... 27 At the upcoming Radiological ...rting Sunday, Royal Philips Electronics ( PHG, AEX...imaging and informatics solutions designed to dire...roviders, by delivering meaningful imaging innovat...e points and easy upgradability. This focus will ...
(Date:11/25/2009)...alif., Nov. 25 Praxis Electronic M...e American Academy of Family Physicians, (AAFP) Fa...faction Survey for improving medical quality, heal...al for new ARRA Stimulus legislation. Praxis also ... positive effect in determining their salary. Fina...
(Date:11/25/2009)...o., Nov. 25 Heska Corpor...advanced diagnostic and specialty products to the ...th Roche Diagnostics Corporation for the supply of... the veterinary market. ,, (Logo: http://w..., "Heska and Roche share the same passion for i...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Can a plant be altruistic 3F 10687 1Can a plant be altruistic 3F 10687 2New mechanism explains how the body prevents formation of blood vessels 10682 1New mechanism explains how the body prevents formation of blood vessels 10682 2BPA Tied to Impotence in Men 61131 1BPA Tied to Impotence in Men 61131 2BPA Tied to Impotence in Men 61131 3
...IN, N.J., July 14 SyntheMed, Inc. (OTC,Bulletin B... development,and commercialization of anti-adhesio...nts, announced today that REPEL-CV(R), the company...uction of adhesions,following cardiac surgery, has...ric patients who undergo open heart surgery. REPEL...
...TAIN VIEW, Calif., July 14 MAP,Pharmaceuticals, I...ted its,Phase 3 clinical program to evaluate MAP00...4 is orally inhaled and self-administered at home ...haler. In the company,s prior Phase,2 efficacy stu...minutes,with relief sustained through at least 24 ...
Other Medicine Technology:SyntheMed Receives Canadian Approval for REPEL-CV(R) 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4
(Date:11/27/2009)...Biotech firm Replikins Ltd. today issued its lates...ata. It shows that the lethality of the virus has...e virus,s current outbreak in the spring of 2009 t...d. 0.1). The H1N1 infectivity count, however, rema...PRWEB) November 27, 2009 -- Biotech firm Replikins...
(Date:11/27/2009)... Israel, Nov. 27 Shamir ...), a leading provider of innovative products and t... today that its board of directors had declared a ...$ 10 million (approximately NIS 37.62 million base...exchange), or approximately US$ 0.609 (approximate...
(Date:11/27/2009)...Voyant Health™ announced today that Spectrum...TraumaCad Enterprise orthopedic templating solutio... (PRWEB) November 27, 2009 -...um Health (Grand Rapids, Michigan) has licensed it...ion and its TraumaCad Extend workflow solution, to...
(Date:11/26/2009)....J., Nov. 27 The diabetes populati...e next 25 years and annual medical spending on the... $113 billion today, according to a study publishe...ational Changing Diabetes ® Program (NCDP), ...is by a team from the University of Chicago. ,,...
(Date:11/26/2009)...No more letters from the North Pole, Textsanta.net...es from Santa , North Pol...nal efficiencies at the North Pole Santa Claus has...l over the globe informed of his Christmas progres...search department have identified a large and grow...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...have shown that positron emission tomography (PET)...eful than mammography and ultrasound in predicting...erefore, the patients ultimate likelihood of survi... procedure was used to measure the accumulation of...
...ty Karolinska Institutet (KI) and the Swedish Inst...entified the biochemical mechanism behind the adhe...s malaria in children. The knowledge of how the ma... year. , Severe anaemia, respiratory problems and...
...black women, report finds , , TUESDAY, Sep...s continue to decline more than 2 percent annually... detection and better treatments, according to a n...007, about 178,480 new cases of invasive breast ca...
...improve health and welfare of ... Morris Animal Foundation (MAF),provides a unique ...te love,for and help animals via its animal health...ed to sponsor or co-sponsor with a,total gift of $...
...Findings Regarding Disease Management in the Work...pport the Need for Those with Chronic Conditions o... Medical ID, HOUSTON, Sept. 25 American Medical... and cost,implications of treatment in a medical e...
... doctor,with a big idea compete against the likes ...rsonal health records (PHR) arena? Steven M. Hacke...Bo Burlingham,s book Small,Giants where companies ...ng because it gives,healthcare consumers tools to ...
Other Medicine News:Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:How adhesive protein causes malaria 2Health News:Breast Cancer Death Rates Continue to Fall 2Health News:Breast Cancer Death Rates Continue to Fall 3Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 2Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 3Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 2Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 3Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 4Health News:Small Town Doctor Takes on Giants in Consumer Healthcare 2
AgileTrac™ Patient Flow
Radianse Indoor Positioning Patient Location
...acutainer Eclipse Blood Collection Needle consists...tegrated with a safety shield aligned to the bevel...BD Vacutainer Eclipse Blood Collection Needle has ...to attach a secondary safety accessory. Immediate,...
Diana incubator
Medicine Products: